Acorda Therapeutics (NSDQ:ACOR) submitted a marketing authorization application to the European Medicines Agency for its inhaled Parkinson’s disease therapy, Inbrija, according to the Ardsley, N.Y.-based company.
The investigational drug is designed to treat people with Parkinson’s disease who are experiencing “off” periods, or a re-emergence of symptoms.
Get the full story at our sister site, Drug Delivery Business News.
The post Acorda seeks EU approval for inhaled Parkinson’s disease drug appeared first on MassDevice.
from MassDevice https://ift.tt/2pFLwJr
Cap comentari:
Publica un comentari a l'entrada